share_log

Endexx Q3 Year-Over-Year Quarterly Sales Increase 246%

Endexx Q3 Year-Over-Year Quarterly Sales Increase 246%

Endexx第三季度销售额同比增长246%
GlobeNewswire ·  2022/08/15 15:50

ENDEXX

尾数

Endexx Top Two Sellers in Pharmacies
Endexx在药店的前两名销售商

Endexx Announces Fiscal Third Quarter 2022

Endexx宣布2022财年第三季度

CAVE CREEK, AZ, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC: EDXC), a provider of innovative plant based and sustainable health and skincare products now available in 8,000 Mass Retail and Pharmacy stores nationwide, today announced its Form 10Q, third quarter ending June 30, 2022.  Endexx continues to rebound and show growth in mass retail sales. The 8000 mass retail stores are in the early stages of growth and are anticipated to fluctuate and grow over the remainder of fiscal 2022 and accelerate in 2023 and 2024 respectively.  Endexx reported $418,151 in revenues in its third quarter of fiscal 2022 versus $120,801 in the third quarter of fiscal 2021, a 246% increase. Additionally, nine-month numbers showed an increase of 127% with $947,428 in the first 3 fiscal quarters of 2022 over $416,094 in the same period of fiscal 2021.­­­­­

亚利桑那州CaveCreek,2022年8月15日(Global Newswire)--Via NewMediaWire-Endexx Corporation(场外交易代码:EDXC)是一家以植物为基础的创新健康和护肤产品供应商,目前在全国8,000家大众零售和药店都有销售,该公司今天宣布了截至2022年6月30日的第三季度10Q报表。Endexx继续反弹,大众零售额出现增长。8000家大众零售店正处于增长的早期阶段,预计将在2022财年剩余时间内波动和增长,并分别在2023年和2024年加速增长。Endexx报告其2022财年第三季度的收入为418,151美元,而2021财年第三季度的收入为120,801美元,增长了246%。此外,9个月的数据显示,2022财年前3个季度的947,428美元比2021财年同期的416,094美元增长了127%。

"The third quarter showed continued expansion in revenues in Mass Retail stores. We currently are in the top two National Pharmacies and the largest premium Mass Retailer in the US," stated CEO Todd Davis. Davis added, "Opening orders in mass retail is the beginning of long-term sales cycles, expansion requires investment and Endexx has managed the challenges of this growth cycle as efficiently as possible given the current financial markets." Davis concluded, "With ongoing anticipation of Federal Regulatory advances, we believe this industry is still in its infancy and has the potential to become a leading multi-billion dollar growth industry in the next few years. According to Nielsen Ratings, Endexx's topical balm and topical cream are the Top Two selling CBD topical products in the pain aisle in Nationwide Pharmacies."

首席执行官托德·戴维斯表示:“第三季度大众零售店的收入持续增长。我们目前跻身全国药店前两名,也是美国最大的高端大众零售商。”Davis补充说:“大众零售的开盘订单是长期销售周期的开始,扩张需要投资,鉴于目前的金融市场,Endexx已经尽可能有效地应对了这一增长周期的挑战。”戴维斯总结说:“随着对联邦监管机构进步的持续预期,我们相信这个行业仍处于初级阶段,有可能在未来几年成为一个领先的数十亿美元增长行业。根据尼尔森评级公司的数据,Endexx的外用药膏和外用乳膏是全国药店最畅销的CBD外用产品。”

Recorded in Q3 financials is an extraordinary non-cash derivative liability.  This is due to the Double Diamond trading in April that allowed below market trading prices to be posted in time and sales records in quotation services. Endexx is working to correct the condition that created the non-cash derivative loss.

在第三季度财务报表中记录了一项特殊的非现金衍生品负债。这是由于4月份的双钻石交易使低于市场交易价的交易得以及时公布,并在报价服务中创造了销售记录。Endexx正在努力纠正造成非现金衍生品亏损的情况。

See 10Q filing at:

请参阅以下地址的10Q备案:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001109486/000149315222022763/form10-q.htm

Https://www.sec.gov/ix?doc=/Archives/edgar/data/0001109486/000149315222022763/form10-q.htm

Learn more about Endexx at:

有关Endexx的更多信息,请访问:

&

&

To find Endexx products visit:

要查找Endexx产品,请访问:

Visit and search for Blesswell or,

访问和搜索布莱斯韦尔或,

Endexx highly recommends our customers and stakeholders to discover the value and experience our Blesswell™ Skincare products. Visit to learn more.

Endexx强烈建议我们的客户和利益相关者发现我们的价值并体验我们的百威™护肤品。访问以了解更多信息。

Try the top 2 selling products in the pain aisle

试试痛苦过道里最畅销的两款产品

Go to high performance Men's Grooming Products at:

请访问高性能男士美容产品网站:

For a store located near you, visit websites below.

对于位于您附近的商店,请访问下面的网站。

For more information about Endexx Corporation:

欲了解有关Endexx公司的更多信息,请访问:

Visit:  , , , and

访问:、、和

About Endexx Corporation

关于Endexx公司

Endexx Corporation, develops and distributes all-natural plant-derived topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs and oils all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and the support of skin health.

Endexx公司,开发和分销全天然植物衍生局部护肤品。它的产品种类繁多,从香膏、面霜、乳液、黄油、面膜、磨砂膏和油,所有这些都是为了健康皮肤和美容健康。这些产品背后的科学包括十年的现场临床研究和实验室工作,以提供含有最佳吸收和支持皮肤健康的成分的功能配方。

Safe Harbor Notice

安全港通告

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.

本新闻稿可能包含1995年私人证券诉讼改革法所指的“前瞻性陈述”,例如与财务结果和未来发展活动计划有关的陈述,因此具有前瞻性。前瞻性陈述包括所有不是关于公司、其董事或高级管理人员的意图、信念或当前期望的历史事实的陈述。请投资者注意,任何此类前瞻性陈述都不是对未来业绩的保证,涉及风险和不确定性,其中许多风险和不确定性超出了公司的控制能力。实际结果可能与前瞻性陈述中预测的结果大不相同。可能导致实际结果与前瞻性陈述中指出的大不相同的因素包括与公司总体业务和财务有关的风险和不确定因素,包括继续和管理其增长、竞争、全球经济状况的能力,以及在公司提交给证券交易委员会的定期报告中详细讨论的其他因素。该公司没有义务更新任何前瞻性陈述。

Contact:
For further investor and media information, contact:
Endexx Corporation
Todd Davis
Chairman & CEO
Endexx@endexx.com
480-595-6900

联系方式:
欲了解更多投资者和媒体信息,请联系:
Endexx公司
托德·戴维斯
董事长兼首席执行官
邮箱:endexx@endexx.com
480-595-6900

Attachment

依附

  • ENDEXX
  • 尾数

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发